發(fā)布時間：2018-05-10 13:15

  本文選題：非布司他 + 高尿酸血癥　； 參考：《南昌大學》2015年碩士論文

【摘要】：目的:系統(tǒng)評價非布司他對比別嘌醇治療高尿酸血癥的療效與安全性。方法:檢索Pub Med、MEDLINE、ISI Web of knowledge、CNKI、CBM、萬方等數(shù)據(jù)平臺,檢索年限從2004年9月至2014年9月,納入非布司他及別嘌醇治療高尿酸血癥的隨機對照試驗,進行質量評價,運用Revman5.0軟件對兩藥治療高尿酸血癥的療效及安全性進行Meta分析。結果:共納入7篇文獻,截止至最后隨訪,非布司他組血清尿酸值達標的患者比例明顯高于別嘌醇組(69.5%vs 43.6%;OR=3.38;95%CI,1.96-5.81;P0.01)。亞組分析顯示:非布司他40mg/d比別嘌醇100~300mg/d有更高比例的患者達到目標血清尿酸值(50.6%vs 46.1%;OR=1.22;95%CI,1.02-1.45;P=0.03)。隨著非布司他劑量增加至(80、120mg/d),達到目標血清尿酸值的患者比例明顯升高(分別為72.8%、82.0%)在副作用方面非布司他和別嘌醇沒有明顯的差距。結論:非布司他(40~120mg/d)比別嘌醇(100~300mg/d)降尿酸效果更好。安全性方面非布司他和別嘌醇相似。
[Abstract]:Objective: to evaluate the efficacy and safety of nonbuflast compared with allopurinol in the treatment of hyperuricemia. Methods: the data platforms such as Pub Medine MEDLINEISI Web of knowledge CNKICBM were searched. The retrieval period was from September 2004 to September 2014, and the quality evaluation was carried out in a randomized controlled trial of the treatment of hyperuricemia with non-Budestar and allopurinol. The efficacy and safety of two drugs in the treatment of hyperuricemia were analyzed by Meta software Revman5.0. Results: by the end of the last follow-up, the proportion of patients in the non-Budesta group who had met the level of serum uric acid was significantly higher than that in the allopurinol group (69.5 vs 43.6%). Subgroup analysis showed that a higher proportion of patients with 40mg/d than allopurinol 100~300mg/d reached the target serum uric acid value of 50.6 vs 46.1%. There was no significant difference in side effects between nonbusultan and allopurinol in side effects with the increase of the dose of non-busultan to 80120 mg / d, the proportion of patients who reached the target serum uric acid level increased significantly (72.8% 82.0, respectively). Conclusion: compared with allopurinol (100 mg / d), busultadine (40mg / d) is more effective than allopurinol (300mg / d) in reducing uric acid. In terms of safety, it is similar to allopurinol.
【學位授予單位】：南昌大學
【學位級別】：碩士
【學位授予年份】：2015
【分類號】：R589.7

【參考文獻】

相關期刊論文 前7條

1 段宇;劉超;;《高尿酸血癥和痛風治療中國專家共識》解讀[J];國際內分泌代謝雜志;2013年06期

2 王麗英;趙燕;鄭毅;李小霞;張曉;徐建華;吳華香;胡紹先;趙蔭環(huán);張風肖;周彬;蘇厚恒;肖征宇;孫瑞華;王國春;;隨機雙盲三模擬對照多中心臨床研究非布索坦降低痛風患者高尿酸水平的療效和安全性[J];中華臨床醫(yī)師雜志(電子版);2013年07期

3 周弋;齊慧;趙根明;楊黎明;孫喬;;上海市浦東新區(qū)居民高尿酸血癥與慢性腎病相關性研究[J];中華流行病學雜志;2012年04期

4 王德光;郝麗;戴宏;陳衛(wèi)東;張道友;李龍海;劉智;韓久懷;葉麗萍;白友為;;安徽省成人慢性腎臟病流行病學調查[J];中華腎臟病雜志;2012年02期

5 閻勝利;趙世華;李長貴;王顏剛;王萍;王忠超;王芳;陳穎;王飛;苗志敏;;山東沿海居民高尿酸血癥及痛風五年隨訪研究[J];中華內分泌代謝雜志;2011年07期

6 鄒貴勉;黃江燕;車文體;眭維國;董力;陳潔晶;向月應;鄒和群;;廣西城市社區(qū)居民高尿酸血癥流行病學調查及其與慢性腎臟病的關系[J];中華內分泌代謝雜志;2011年07期

7 施桂英;;走出痛風性關節(jié)炎診斷和治療的誤區(qū)[J];中華全科醫(yī)師雜志;2006年09期

，

本文編號：1869456